JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Search

Simulations Plus Inc

Gesloten

SectorGezondheidszorg

13.85 -2.05

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

13.77

Max

14.18

Belangrijke statistieken

By Trading Economics

Inkomsten

-70M

-67M

Verkoop

-2.1M

20M

K/W

Sectorgemiddelde

48.528

34.393

EPS

0.31

Dividendrendement

0.48

Winstmarge

-330.585

Werknemers

243

EBITDA

-79M

-74M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+65.1% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.48%

2.54%

Volgende Winsten

22 okt 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-90M

261M

Vorige openingsprijs

15.9

Vorige sluitingsprijs

13.85

Nieuwssentiment

By Acuity

55%

45%

309 / 374 Rangschikking in Healthcare

Simulations Plus Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 aug 2025, 17:49 UTC

Belangrijke Marktbewegers

180 Life Sciences Stock Jumps on $156 Million Notes Sale

11 aug 2025, 17:18 UTC

Belangrijke Marktbewegers

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

11 aug 2025, 16:25 UTC

Winsten

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

11 aug 2025, 23:50 UTC

Marktinformatie

Nikkei May Rise as Yen Weakens -- Market Talk

11 aug 2025, 23:42 UTC

Marktinformatie

Global Energy Roundup: Market Talk

11 aug 2025, 23:42 UTC

Marktinformatie

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

11 aug 2025, 23:36 UTC

Marktinformatie

Gold Edges Higher on Likely Technical Recovery -- Market Talk

11 aug 2025, 23:32 UTC

Marktinformatie

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

11 aug 2025, 23:02 UTC

Marktinformatie

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

11 aug 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

11 aug 2025, 20:37 UTC

Winsten
Acquisities, Fusies, Overnames

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

11 aug 2025, 20:37 UTC

Winsten
Acquisities, Fusies, Overnames

Bakkt Holdings 2Q Rev $577.9M >BKKT

11 aug 2025, 20:37 UTC

Winsten
Acquisities, Fusies, Overnames

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

11 aug 2025, 20:22 UTC

Winsten

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

11 aug 2025, 20:22 UTC

Winsten

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

11 aug 2025, 20:22 UTC

Winsten

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

11 aug 2025, 20:22 UTC

Winsten

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

11 aug 2025, 20:22 UTC

Winsten

Exodus Movement 2Q Rev $25.8M >EXOD

11 aug 2025, 20:14 UTC

Marktinformatie

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

11 aug 2025, 19:12 UTC

Marktinformatie

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

11 aug 2025, 18:56 UTC

Marktinformatie

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

11 aug 2025, 18:31 UTC

Marktinformatie

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

11 aug 2025, 17:43 UTC

Marktinformatie

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

11 aug 2025, 17:28 UTC

Marktinformatie

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

11 aug 2025, 17:16 UTC

Marktinformatie

Commodity Longs Fall to 11-Month Low -- Market Talk

11 aug 2025, 16:42 UTC

Acquisities, Fusies, Overnames

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

11 aug 2025, 16:27 UTC

Acquisities, Fusies, Overnames

BBVA Says Sabadell Offer Remains in Effect

11 aug 2025, 16:26 UTC

Acquisities, Fusies, Overnames

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

11 aug 2025, 16:25 UTC

Acquisities, Fusies, Overnames

Banco de Sabadell Announced TSB Sale on July 1

11 aug 2025, 16:25 UTC

Acquisities, Fusies, Overnames

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Peer Vergelijking

Prijswijziging

Simulations Plus Inc Prognose

Koersdoel

By TipRanks

65.1% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 22.9 USD  65.1%

Hoogste 31 USD

Laagste 13.5 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor Simulations Plus Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

7 ratings

4

Buy

3

Hold

0

Sell

Sentiment

By Acuity

309 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.